Source:Reports of Practical Oncology & Radiotherapy, Volume 23, Issue 3
Author(s): Patrycja Czerwińska, Sylwia Mazurek, Maciej Wiznerowicz
As soon as induced pluripotent stem cells (iPSCs) reprogramming of somatic cells were developed, the discovery attracted the attention of scientists, offering new perspectives for personalized medicine and providing a powerful platform for drug testing. The technology was almost immediately applied to cancer studies. As presented in this review, direct reprogramming of cancer cells with enforced expression of pluripotency factors have several basic purposes, all of which aim to explain the complex nature of cancer development and progression, therapy-resistance and relapse, and ultimately lead to the development of novel anti-cancer therapies. Here, we briefly present recent advances in reprogramming methodologies as well as commonalities between cell reprogramming and carcinogenesis and discuss recent outcomes from the implementation of induced pluripotency into cancer research.
https://ift.tt/2KdlBl1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου